1266 related articles for article (PubMed ID: 30959046)
21. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.
Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G
J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846
[TBL] [Abstract][Full Text] [Related]
22. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.
Zhang DM; Li YJ; Shu C; Ruan ZX; Chen WM; Yiu A; Peng YH; Wang J; Lan P; Yao Z; Fung KP; Fu LW; Chen ZS; Ye WC
Anticancer Drugs; 2013 Jun; 24(5):441-54. PubMed ID: 23466650
[TBL] [Abstract][Full Text] [Related]
23. Co-Inhibition of P-gp and Hsp90 by an Isatin-Derived Compound Contributes to the Increase of the Chemosensitivity of MCF7/ADR-Resistant Cells to Doxorubicin.
Abdalla AN; Di Stefano M; Poli G; Tuccinardi T; Bader A; Vassallo A; Abdallah ME; El-Readi MZ; Refaat B; Algarni AS; Ahmad R; Alkahtani HM; Abdel-Aziz AA; El-Azab AS; Alqathama A
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011321
[TBL] [Abstract][Full Text] [Related]
24. Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation.
Li S; Zhao Q; Wang B; Yuan S; Wang X; Li K
Phytother Res; 2018 Aug; 32(8):1530-1536. PubMed ID: 29635751
[TBL] [Abstract][Full Text] [Related]
25. Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells.
Dinić J; Podolski-Renić A; Jovanović M; Musso L; Tsakovska I; Pajeva I; Dallavalle S; Pešić M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527404
[TBL] [Abstract][Full Text] [Related]
26. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
27. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
Abdin SM; Tolba MF; Zaher DM; Omar HA
Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
[TBL] [Abstract][Full Text] [Related]
28. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
29. Understanding dihydro-β-agarofuran sesquiterpenes from Tripterygium hypoglaucum as the modulators of multi-drug resistance in HepG2/Adr cells.
Yang T; Wang S; Zheng H; Wang L; Liu D; Chen X; Li R
Biochem Biophys Res Commun; 2019 Jan; 508(3):742-748. PubMed ID: 30528235
[TBL] [Abstract][Full Text] [Related]
30. Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
Teodori E; Braconi L; Bua S; Lapucci A; Bartolucci G; Manetti D; Romanelli MN; Dei S; Supuran CT; Coronnello M
Molecules; 2020 Apr; 25(7):. PubMed ID: 32290281
[TBL] [Abstract][Full Text] [Related]
31. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
Zhu HJ; Wang JS; Guo QL; Jiang Y; Liu GQ
Biol Pharm Bull; 2005 Oct; 28(10):1974-8. PubMed ID: 16204958
[TBL] [Abstract][Full Text] [Related]
32. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
33. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
Ji BS; He L
J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
[TBL] [Abstract][Full Text] [Related]
34. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
Li YS; Yang X; Zhao DS; Cai Y; Huang Z; Wu R; Wang SJ; Liu GJ; Wang J; Bao XZ; Ye XY; Wei B; Cui ZN; Wang H
Eur J Med Chem; 2021 Apr; 216():113336. PubMed ID: 33725657
[TBL] [Abstract][Full Text] [Related]
36. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
37. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
38. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro.
Gao A; Liang H; Wang X; Zhang X; Jing M; Zhang J; Yan Y; Xiang W
Eur J Pharmacol; 2011 Jun; 659(2-3):108-13. PubMed ID: 21458446
[TBL] [Abstract][Full Text] [Related]
39. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K
Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255
[TBL] [Abstract][Full Text] [Related]
40. Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin.
Yuan Z; Shi X; Qiu Y; Jia T; Yuan X; Zou Y; Liu C; Yu H; Yuan Y; He X; Xu K; Yin P
Oncol Rep; 2017 Mar; 37(3):1815-1825. PubMed ID: 28184922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
